Outlook Therapeutics (OTLK) announced it has re-submitted its Biologics License Application, BLA, to the U.S. Food and Drug Administration, FDA, for ONS-5010, after receiving the official minutes from the FDA Type A meeting conducted in September 2025. ONS-5010 is an investigational ophthalmic formulation of bevacizumab which, if approved, will be branded as LYTENAVA for the treatment of wet age-related macular degeneration.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK:
- Outlook Therapeutics: Hold Rating Amid Uncertainties in BLA Resubmission and Market Challenges
- Outlook Therapeutics Completes FDA Meeting on ONS-5010
- Outlook Therapeutics says plans to resubmit BLA before end of CY25
- Outlook Therapeutics says had ‘productive’ discussion with FDA
- Largest borrow rate increases among liquid names